ALIOF Stock UPDATES Actelion Ltd (ALIOF) 118.8399 09/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actelion Ltd (ALIOF) 118.8399 $ALIOF

Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute

Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.

Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.

Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:34PM CDT
Gilead (GILD) received a favorable verdict on Sovaldi.

TrovaGene (TROV) Worth Watching: Stock Rises 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:39AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as its shares rose almost 9% on the day.

NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose almost 9% on the day.

Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.

Epizyme (EPZM) Crumbles: Stock Falls by 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:33AM CDT
Epizyme has been witnessing a flat movement in its earnings estimate front and its share price has been declining for past 24 hours

Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:20PM CDT
Amgen (AMGN) suffered a major setback when its phase III study, FOCUS on multiple myeloma treatment, Kyprolis did not meet its primary endpoint.

Genomic Health Raised to Buy on Better-than-Expected Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 11:10AM CDT
Genomic Health's (GHDX) sales grossed $70.5 million, up 10.7% year over year, exceeding the Zacks Consensus Estimate of $69 million

Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.

Insmed Incorporated (INSM) in Focus: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:39AM CDT
Insmed Incorporated (INSM) was a big mover last session, as its shares rose nearly 11% on the day.

InterMune (ITMN) Jumps: Stock Adds 14.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:51AM CDT
InterMune, Inc. (ITMN) was a big mover last session, as its shares rose over 14% on the day.

Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 1:37PM CDT
Shares of Dendreon Corporation (DNDN) were down significantly after the company warned that it will not be able to repay or refinance its notes due 2016.

BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:02PM CDT
Shares of BioDelivery Sciences International, Inc. (BDSI) jumped 7.58 % after the company reported its second-quarter 2014 results.

Myriad Genetics' Q4 Earnings Beat Estimates, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:40AM CDT
In the fourth quarter, Myriad Genetics' (MYGN) total revenue climbed 8.4% year over year to $188.8 million, beating the Zacks Consensus Estimate of $187 million by a whisker.

Intercept Pharmaceuticals (ICPT) Worth Watching: Stock Gains 16.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:25AM CDT
Intercept Pharmaceuticals (ICPT) was a big mover last session, with shares rising nearly 17% on the day.

Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:20PM CDT
Regeneron's (REGN) Eylea has been approved for a third indication in the EU.

Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:49PM CDT
Sarepta reported second quarter loss of 85 cents per share compared to a loss of 60 cents per share in the year-ago quarter.

MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents




Scroll down for more posts ▼

Top 10 Most Recent News Articles

SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 11

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 43

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 16

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 234

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 114

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Microsoft-Intel Azure Pact Puts Systems Work First

Updated Category News Views 18

Azure’s next bottleneck may be the plumbing between chips, not the chips alone. Microsoft and Intel announced on Nov. 18, 2026, a long-term expansion of their already ancient partnership aimed at shaping select pieces of Azure infrastructure for cloud and AI demand. That sounds dry, because infrastructure announcements usually do. But this one deserves a closer look: it...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 134

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading

Top 5 Most Recently Viewed Articles

Symbotic Inc. Faces Legal Challenges Amid Financial Irregularities

Updated Category News Views 138

Symbotic Inc. Under Investigation for Securities Violations There has been a significant development for investors of Symbotic Inc. As concerns about the Company’s financial practices have arisen, the Schall Law Firm has initiated an investigation. This effort is aimed at ensuring shareholders are informed and protected amid allegations of misleading statements related...

Continue Reading
Turning Point Brands: Growth Opportunities Ahead with New Rating

Updated Category News Views 103

Turning Point Brands Gets a Positive Buy Rating Recently, Turning Point Brands (NYSE: TPB) earned a favorable Buy rating from Roth/MKM, along with a price target set at $50. This company is known for its wide range of consumer brands in the nicotine, tobacco, and cannabis markets, particularly recognized for its popular rolling papers and moist snuff products. Growth in...

Continue Reading
NeuroSense Therapeutics Celebrates Key Manufacturing Milestone

Updated Category News Views 232

NeuroSense Therapeutics Achieves Commercial Manufacturing Scale-Up NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a pioneering biotechnology firm dedicated to developing innovative treatments for severe neurodegenerative diseases, has announced a major milestone in its commercial journey. The company has successfully scaled up its production of PrimeC, preparing for...

Continue Reading
Discover the Potential of Azapeptides in Peptide Stability

Updated Category News Views 179

Unveiling the Future of Peptide Stability with Azapeptide Synthesis In this informative webinar, participants will discover how strategies involving azapeptides can significantly enhance the stability of peptides and improve workflows related to synthesis. Attendees will delve into techniques for incorporating aza-amino acids within peptides that utilize traditional amino...

Continue Reading
Ascent Solar Technologies Faces Major Challenges in Market

Updated Category News Views 118

Ascent Solar Technologies Hits 52-Week Low Ascent Solar Technologies, recognized for its cutting-edge thin-film photovoltaic modules, is currently going through a challenging period. The company's stock has reached a 52-week low of $2.32, reflecting an astonishing nearly 99.6% decline over the past year. This drastic drop underscores the significant hurdles the company...

Continue Reading